Jiangsu Kanion Pharmaceutical Co.,Ltd. (SHA:600557)
China
· Delayed Price · Currency is CNY 12.64
-0.20 (-1.56%)
Apr 30, 2025, 3:00 PM CST
SHA:600557 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Operating Revenue | 3,898 | 4,840 | 4,323 | 3,614 | 2,985 | Upgrade
|
| Other Revenue | - | 28.27 | 27.46 | 34.95 | 47.42 | Upgrade
|
| Revenue | 3,898 | 4,868 | 4,351 | 3,649 | 3,032 | Upgrade
|
| Revenue Growth (YoY) | -19.93% | 11.88% | 19.25% | 20.34% | -33.60% | Upgrade
|
| Cost of Revenue | 1,044 | 1,255 | 1,214 | 1,024 | 818.9 | Upgrade
|
| Gross Profit | 2,854 | 3,613 | 3,137 | 2,625 | 2,213 | Upgrade
|
| Selling, General & Admin | 1,853 | 2,284 | 2,057 | 1,745 | 1,456 | Upgrade
|
| Research & Development | 638.1 | 771.69 | 605.73 | 499.39 | 380.42 | Upgrade
|
| Other Operating Expenses | -23.69 | 66.87 | 73.07 | 60.8 | 4.29 | Upgrade
|
| Operating Expenses | 2,468 | 3,123 | 2,738 | 2,305 | 1,842 | Upgrade
|
| Operating Income | 386.01 | 489.78 | 399 | 320.11 | 371.33 | Upgrade
|
| Interest Expense | - | - | -1.91 | -11.15 | -23.47 | Upgrade
|
| Interest & Investment Income | 20.52 | 39.25 | 15.35 | 7.64 | 4.21 | Upgrade
|
| Currency Exchange Gain (Loss) | - | 0.06 | 0.15 | - | - | Upgrade
|
| Other Non Operating Income (Expenses) | -2.11 | -1.38 | -0.6 | -0.7 | -57.13 | Upgrade
|
| EBT Excluding Unusual Items | 404.42 | 527.7 | 411.99 | 315.89 | 294.95 | Upgrade
|
| Gain (Loss) on Sale of Assets | 1.08 | 0.76 | 1.38 | 0.97 | -0.3 | Upgrade
|
| Asset Writedown | -20.74 | -2.65 | -0.53 | -2.81 | -0.23 | Upgrade
|
| Other Unusual Items | - | 25.17 | 32.88 | 14.21 | - | Upgrade
|
| Pretax Income | 384.76 | 550.98 | 445.72 | 328.27 | 294.42 | Upgrade
|
| Income Tax Expense | 3.84 | 3.93 | 3.8 | 3.92 | 20.4 | Upgrade
|
| Earnings From Continuing Operations | 380.92 | 547.05 | 441.92 | 324.35 | 274.03 | Upgrade
|
| Minority Interest in Earnings | 10.94 | -10.32 | -7.45 | -3.81 | -11.1 | Upgrade
|
| Net Income | 391.86 | 536.73 | 434.47 | 320.54 | 262.92 | Upgrade
|
| Net Income to Common | 391.86 | 536.73 | 434.47 | 320.54 | 262.92 | Upgrade
|
| Net Income Growth | -26.99% | 23.54% | 35.54% | 21.92% | -48.14% | Upgrade
|
| Shares Outstanding (Basic) | 576 | 577 | 579 | 572 | 598 | Upgrade
|
| Shares Outstanding (Diluted) | 576 | 577 | 579 | 572 | 598 | Upgrade
|
| Shares Change (YoY) | -0.15% | -0.37% | 1.20% | -4.21% | 1.36% | Upgrade
|
| EPS (Basic) | 0.68 | 0.93 | 0.75 | 0.56 | 0.44 | Upgrade
|
| EPS (Diluted) | 0.68 | 0.93 | 0.75 | 0.56 | 0.44 | Upgrade
|
| EPS Growth | -26.88% | 24.00% | 33.93% | 27.27% | -48.84% | Upgrade
|
| Free Cash Flow | 225.8 | 743.52 | 784.85 | 736.77 | 510.78 | Upgrade
|
| Free Cash Flow Per Share | 0.39 | 1.29 | 1.35 | 1.29 | 0.85 | Upgrade
|
| Dividend Per Share | - | 0.372 | 0.220 | - | - | Upgrade
|
| Dividend Growth | - | 69.11% | - | - | - | Upgrade
|
| Gross Margin | 73.22% | 74.21% | 72.11% | 71.95% | 72.99% | Upgrade
|
| Operating Margin | 9.90% | 10.06% | 9.17% | 8.77% | 12.25% | Upgrade
|
| Profit Margin | 10.05% | 11.03% | 9.99% | 8.79% | 8.67% | Upgrade
|
| Free Cash Flow Margin | 5.79% | 15.27% | 18.04% | 20.19% | 16.85% | Upgrade
|
| EBITDA | 585.65 | 676.8 | 588.83 | 507.11 | 530.91 | Upgrade
|
| EBITDA Margin | 15.03% | 13.90% | 13.53% | 13.90% | 17.51% | Upgrade
|
| D&A For EBITDA | 199.64 | 187.02 | 189.83 | 187 | 159.58 | Upgrade
|
| EBIT | 386.01 | 489.78 | 399 | 320.11 | 371.33 | Upgrade
|
| EBIT Margin | 9.90% | 10.06% | 9.17% | 8.77% | 12.25% | Upgrade
|
| Effective Tax Rate | 1.00% | 0.71% | 0.85% | 1.19% | 6.93% | Upgrade
|
| Revenue as Reported | - | 4,868 | 4,351 | 3,649 | 3,032 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.